Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1210 + Hypofraction Radiotherapy in Oligometastatic NSCLC
NCT03557411Phase 2Unknown
- Sponsor
- Shandong Cancer Hospital
- Start
- Jul 2018
- Primary completion
- Jul 2020
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab in non-small cell lung cancer (NSCLC), sponsored by Shandong Cancer Hospital. Primary endpoints: Clinically significant toxicity at 28 days and Progression-Free Survival at 6 months. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03557411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03557411.